SCHEMBL20239261

SCHEMBL20239261

CNS(=O)(=O)Cc1ccc(Oc2cc(CNc3ncc(Cl)cn3)cc(N)n2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 1/20 0.51
KDM4E B2RXH2 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.38
ALDH1A1 P00352 2/20 0.36
RAB9A P51151 1/20 0.36
VNN1 O95497 3/20 0.36
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
CYP2C9 P11712 2/20 0.34
LMNA P02545 2/20 0.33
MET P08581 1/20 0.33
KDR P35968 1/20 0.33
CYP3A4 P08684 1/20 0.33
HTT P42858 1/20 0.33
CYP1A2 P05177 1/20 0.33
MAPT P10636 1/20 0.33
CYP2C19 P33261 1/20 0.33
GLA P06280 1/20 0.32
CLK1 P49759 1/20 0.32
CLK2 P49760 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18249759 0.89 DGAT2 (0.49) DGAT2KDM4ESMN1; SMN2ALDH1A1VNN1
SCHEMBL20239319 0.89 DGAT2 (0.60) DGAT2KDM4ESMN1; SMN2ALDH1A1RAB9A
SCHEMBL20239203 0.85 DGAT2 (0.59) DGAT2KDM4ESMN1; SMN2ALDH1A1RAB9A
SCHEMBL20239154 0.85 DGAT2 (0.46) DGAT2KDM4EALDH1A1RAB9AVNN1
SCHEMBL20239321 0.84 DGAT2 (0.46) DGAT2SMN1; SMN2ALDH1A1RAB9AMEN1
SCHEMBL16738674 0.82 DGAT2 (0.57) DGAT2KDM4ESMN1; SMN2ALDH1A1RAB9A
SCHEMBL20239333 0.82 DGAT2 (0.56) DGAT2KDM4ESMN1; SMN2ALDH1A1RAB9A
SCHEMBL20239153 0.81 DGAT2 (0.43) DGAT2KDM4ESMN1; SMN2VNN1CYP2C9
SCHEMBL18249747 0.81 DGAT2 (0.51) DGAT2KDM4EALDH1A1MEN1KMT2A
SCHEMBL20239171 0.81 DGAT2 (0.56) DGAT2KDM4ESMN1; SMN2ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107635975-B DGAT2 inhibitors 伊莱利利公司 2020-07-24 CN disclosed
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT DGAT2 1/4885KDM4E 4070/4885SMN1; SMN2 4828/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT DGAT2 1/4885KDM4E 3891/4885SMN1; SMN2 4835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.